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Genetic variation influences individual response to the
anticlotting drug clopidogrel, otherwise known as Plavix,
leaving the approximately 30% of Western Europeans
who are poor metabolizers of the drug at an increased risk
of a cardiac event while on treatment. Doctors could switch
tonewer,morepotent antiplatelet drugs that share the same
drug target, but these are associated with increased risk of
bleeding. It therefore seems unwise to use them on all
patients. Theoretically, pharmacogenetic testing could be
used for determining which drug should be prescribed on
an individual basis, but, in an emergency situation, it does
not seem feasible to wait on a genetic test result before
moving forward with treatment. Point-of-care genetic
testing could remove this barrier, and this is exactly what
is tested in recent work reported by Roberts et al. in The
Lancet. In a randomized trial involving patients undergoing
stenting or angioplasty for acute coronary syndrome or
stable angina, Roberts et al. examined whether bedside
pharmacogenetic testing could be used for guidingmedica-
tion choice and, subsequently, for reducing the proportion
of poor clopidogrel metabolizers with high platelet reac-
tivity after sevendays of drug treatment.Nurses at the point
of care could complete their genotyping strategy within an
hour to identify carriers of the CYP2C19*2 allele, which is a
common allele associated with poor response to clopidog-
rel. These carriers could then be treated selectively with a
more potent platelet inhibitor. Although this was a small
study, Roberts et al. found that although none of the
CYP2C19*2 carriers in the genotyped group had a platelet
reactivity above their threshold at seven days, 30% of those
in the untested control group (who all received clopidogrel)
were above this threshold andwere therefore at an increased
risk of a cardiac event. Although larger trials that assess clin-
ical outcomes need to be performed, this at least provides
a proof of principle for bedside pharmacogenetic testing.
Roberts et al. (2012). The Lancet. Published online March
29, 2012. 10.1016/S0140-6736(12)60161-5.
De Novo Mutations and Autism
Although large copy-number variants and mutations in
knownMendelian disease genes all together explain a signif-
icant portion of autism cases, the underlying etiology
remains unknown in the majority of cases. Some hypothe-
size that this is because rare variation inmanydifferent genes
contributes to the disorder, a theory that is supported by1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Amthreepapers recentlypublishedbyNature. Traditional linkage
and associationmethods are not able to detect this variation
because it is rare andnot expected tobe passed through fami-
lies. Thus, Neale et al., O’Roak et al., and Sanders et al. turned
to exome-sequencing strategies inautism-affected families in
an attempt to uncover rare, de novo SNVs that might con-
tribute toautism.This is easier said thandone; simplyfinding
adenovomutation inapersonwith autism isnot enough for
the disorder to be attributed to the mutation. In fact,
modeling by Neale et al. suggests that most of this de novo
variation is irrelevant to autism. To make sense of the varia-
tion, each group used further analyses to pull out the genes
most likely to have relevance, including comparisons of the
variation identified in the full sample of probands and inter-
actionanalyses todeterminewhether thegeneswithdenovo
variants interact closely with each other and with genes
already known to contribute to autism. The genes that float
to the top of the pile include those encoding sodium chan-
nels SCN1A and SCN2A, the chromatin remodeling factor
CHD8, and an axon guidance cue, NTNG1. Are these
sequence variants sufficient to cause autism? According to
Neale et al., probably not. They propose that the de novo
sequence variants must combine with other risk factors to
yield autism. Discerning the global set of genetic risk factors
in an individual will require much more research; O’Roak
et al. estimate that several hundred loci might contribute to
autism. One fact consistent between the three studies is the
correlation between de novo sequence changes and paternal
age, which is interesting given the association between
paternal age and risk of autism.
Neale et al. (2012). Nature. Published online April 4, 2012.
10.1038/nature11011.
O’Roak et al. (2012). Nature. Published online April 4, 2012.
10.1038/nature10989.
Sanders et al. (2012). Nature. Published online April 4,
2012. 10.1038/nature10945.
AWindow into the Future?
The value of personal genome scans is viewed as nil by
some, but the fact that many people have sought these
scans indicates that there is interest in genetic-based health
predictions. Based on genetic associations, current scans
use SNP genotyping. As we move to the predicted era of
whole-genome sequencing for many people, will the
predictions we glean from our genome get better? Roberts
et al. used mathematical modeling based on twin registryta, GA 30322, USA
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data to answer this question. They startedwith the idea that
because monozygotic twins share a genotype, they share
the same genetic risk for any disease. They could thus use
registry data on the health status of the twins to estimate
the distributions of genetic risk that would be consistent
with the data. On the basis of these models and without
genotyping the twins, they could then estimate the
capacity for whole-genome sequencing to produce a
clinically meaningful result for 24 diseases with diverse
etiologies. They found that for 23 of these diseases, most
individuals would receive negative results from whole-
genome sequencing and that these will not reduce the risk
of developing the disease by a substantial amount relative
to the general population risk. On the other hand, more
than 90% of tested individuals should receive a positive
result that indicates a significantly increased risk of at least
one disorder. Although admittedly based onmodeling, this
leavesmewith a couple of questions: Is the identification of
this risk enough to warrant whole-genome sequencing on
a grand scale? And could we ever get to the point where
we can find all of the relevant genetic variation for any
specific complex disease anyway? I guess I need a window
into the future in order to predict the answers myself.
Roberts et al. (2012). Sci. Transl. Med. Published online April
2, 2012. 10.1126/scitranslmed.3003380.
The Challenges of Prenatal Chromosomal Microarray
Compared to standard karyotyping, chromosomal micro-
arrays (CMAs) have increased the diagnostic sensitivity of
cytogenetic testing, and CMAs are now a first tier test for
intellectual disability and autism. Trials are underway to
move CMAs into the prenatal setting, which presents
unique challenges. Rather than trying to explain a pheno-
type, as we do in a diagnostic setting, prenatal testing
involves predicting the future, something that can be chal-
lenging when changes of uncertain significance or those
associated with variable expressivity are detected. These
challenges are discussed in two recent articles in a special
issue of Prenatal Diagnosis. Wapner et al. use real CMA
results generated via a National Institute of Child Health
and Human Development (NICHD)-sponsored clinical
trial of prenatal CMAs in order to illustrate several issues
of uncertainty that can arise in prenatal CMA testing.
McGillivray et al. explore ethical aspects of the use of
prenatal CMAs; such aspects are patient autonomy in deci-
sion-making, informed choice in genetic testing, and the758 The American Journal of Human Genetics 90, 757–759, May 4, 2moral responsibility of the physician when an elective
termination is performed on the basis of CMA results.
Both articles stress the role of appropriate counseling
before and after the test to help families make the best
use of prenatal CMA. It is important to keep in mind
that uncertainties that arise from prenatal CMAs are not
new; there are no guarantees in prenatal testing no matter
what approach is taken. On the other hand, the closer you
look at the genome, the more you’ll find. This type of
discussion is therefore important for ensuring the most
effective delivery of this testing to patients.
McGillivray et al. (2012). Prenatal Diagnosis 32, 389–395.
10.1002/pd.3849.
Wapner et al. (2012). Prenatal Diagnosis 32, 396–400.
10.1002/pd.3863.
On Second Look.
For years, the estimated number of imprinted genes in the
genome was somewhere around 100–200. The advent of
whole-transcriptome sequencing (RNA-Seq) provided an
opportunity for researchers to look genome-wide for
imprinted genes, an approach that was taken by a couple
of recent papers that examined transcripts from reciprocal
mouse crosses (Science 329, 682–685 and Science 329, 643–
648). The data therein suggested that the number of
imprinted genes might, in fact, be an order of magnitude
higher than previously estimated, which startled many
researchers. DeVeale et al. were fascinated by this finding
but had problems confirming it. They did further analyses
of the RNA-Seq data and found that, in fact, many of the
novel imprinted genes discovered via RNA-Seq are actually
false positives. To estimate the false-discovery rate, the
researchers did a mock reciprocal cross in which they
used RNA-Seq data from samples with the same parental
backgrounds (rather than reciprocal backgrounds) and
found almost as many ‘‘imprinted’’ gene calls as were
observed with the true reciprocal crosses. They also found
that SNPs from the same coding exon but from different
sequence reads often gave discrepant results for allele-
specific expression, which is hard to reconcile. DeVeale
et al. revised the estimate of imprinted genes back down
closer to what it had been, and they also use their analyses
to propose criteria that could be used to predict the likeli-
hood that a putative imprinted gene will be validated.
DeVeale et al. (2012). PLoS Genetics 8, e1002600. 10.1371/
journal.pgen.1002600.This Month in Our Sister JournalsA New Use for the TDT
Picking which allele a child inherits from a parent is like
a flip of a coin, or so we like to say when we’re teachingbasic genetic principles. Sometimes, this is not true and
there is a deviation from this randomness that is termed
transmission distortion. This could have something to do012
with an allele influencing the gametes, such as a process
that alters the allele ratios during meiosis or one that influ-
ences how likely it is that a gamete will lead to a successful
fertilization. This distortion could, on the other hand,
reflect a difference in the viability of the resulting embryo.
Examples of transmission-distorting alleles have been
found in models systems, but little is known about them
in humans. Meyer et al. were interested in studying this
phenomenon in humans on a genome-wide scale. The
tactic they took used the transmission disequilibrium
test, or TDT. The TDT was designed to look for alleles
that were not passed randomly from parents to children
as a way to detect genetic association with traits of interest,
but Meyer et al. realized it could instead be used to detect
transmission distortion from heterozygous parents regard-The Amless of the phenotype of the children. They applied the
TDT to three large datasets: the Framingham Heart Study
(FHS), the AGRE sample, and a Hutterite sample. One
promising candidate region on chromosome 10 exhibits
transmission distortion in the AGRE sample and overlaps
a region that had previously shown distortion in aHapMap
sample. Beyond this, their analyses turned out to be very
sensitive to genotyping error, which confounded the
results from the FHS and Hutterite samples. Turning
lemons into lemonade, the authors propose that this
type of analysis could be used to identify SNPs that are
more subject to genotype error via array-based genotyping
platforms.
Meyer et al. (2012). Genetics. Published online February 29,
2012. 10.1534/genetics.112.139576.erican Journal of Human Genetics 90, 757–759, May 4, 2012 759
